BioNxt Solutions Inc. (CVE:BNXT) | WebDisclosure

Basculer en Français

9478	Companies
185484	Keywords
117839	Articles
99329	Press releases

Headlines Articles Press releases BioNxt Solutions Inc.

Home
Companies
BioNxt Solutions Inc.

PRESS RELEASE

published on 09/26/2024 at 09:05, 1 year 2 months ago

BioNxt Provides Update on Cladribine Program for Multiple Sclerosis, Sublingual Neurodegenerative Disease Patent, and Investor Relations Activities
BioNxt Solutions Inc. updates on sublingual Cladribine drug formulation program for Multiple Sclerosis, patent applications, and investor relations activities. Company aims to revolutionize drug delivery systems for CNS diseases

Investor Relations BioNxt Solutions Inc. Multiple Sclerosis Cladribine Patent Application
BRIEF

published on 09/09/2024 at 22:35, 1 year 2 months ago

BioNxt Receives Positive International Examination Report From the European Patent Office

Multiple Sclerosis BioNxt Solutions European Patent Office Sublingual Drug Delivery Myasthenia Gravis
BRIEF

published on 09/09/2024 at 22:35, 1 year 2 months ago

BioNxt reçoit un rapport d'examen international positif de l'Office européen des brevets

Sclérose En Plaques Solutions BioNxt Office Européen Des Brevets Administration Sublinguale De Médicaments Myasthénie Grave
PRESS RELEASE

published on 09/09/2024 at 22:30, 1 year 2 months ago

BioNxt Receives Positive International Examination Report From the European Patent Office for Broad Patent Application for Sublingual Delivery of Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases
BioNxt Solutions Inc. receives positive international examination report from the European Patent Office for sublingual delivery patent application. Company to expand patent portfolio for neurodegenerative diseases and MS market

BioNxt Solutions Inc. Multiple Sclerosis Patent Application Neurodegenerative Diseases European Patent Office
BRIEF

published on 08/15/2024 at 09:10, 1 year 3 months ago

BioNxt Signs Letter of Intent with Gen-Plus GmbH & Co KG for Potential Business Collaborations

Partnership Cladribine Pharmaceutical Development BioNxt Solutions Gen-Plus GmbH
BRIEF

published on 08/15/2024 at 09:10, 1 year 3 months ago

BioNxt signe une lettre d'intention avec Gen-Plus GmbH & Co KG pour d'éventuelles collaborations commerciales

Partenariat Cladribine Développement Pharmaceutique Solutions BioNxt Gen-Plus GmbH
PRESS RELEASE

published on 08/15/2024 at 09:05, 1 year 3 months ago

BioNxt Signs Letter of Intent with Gen-Plus GmbH & Co KG for Potential Business Collaborations
BioNxt Solutions Inc. signs non-binding LOI with Gen-Plus GmbH & Co KG, part of Conscio Group, for potential cooperation in pharmaceutical products and clinical trials. Details to follow

Clinical Trials Pharmaceutical BioNxt Solutions Inc. LOI Gen-Plus GmbH
BRIEF

published on 07/17/2024 at 09:10, 1 year 4 months ago

BioNxt Signs Statement of Work with International CRDMO for Cladribine ODF Development

Multiple Sclerosis Pharmaceutical Development BioNxt Solutions Cladribine ODF CRDMO
BRIEF

published on 07/17/2024 at 09:10, 1 year 4 months ago

BioNxt signe une déclaration de travail avec le CRDMO international pour le développement de la cladribine ODF

Sclérose En Plaques Développement Pharmaceutique Solutions BioNxt Cladribine ODF CRDMO
PRESS RELEASE

published on 07/17/2024 at 09:05, 1 year 4 months ago

BioNxt Signs Statement of Work with International Contract Research, Development, And Manufacturing Organization for Cladribine ODF Development
BioNxt Solutions Inc. signs agreement with German CRDMO for Cladribine oral dissolvable film development program targeting the lucrative multiple sclerosis market

BioNxt Solutions Inc. Cladribine CRDMO Oral Dissolvable Film MS Market

Accesswire

Published on 12/05/2025 at 15:35, 8 minutes ago

XCF Global Moves to Double SAF Production with New Rise Reno Expansion
Published on 12/05/2025 at 15:25, 18 minutes ago

Usha Resources Provides Corporate Updates
Published on 12/05/2025 at 15:00, 43 minutes ago

Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Published on 12/05/2025 at 14:00, 1 hour 43 minutes ago

Ocean Power Technologies Attending the 3rd Annual DealFlow Discovery Conference
Published on 12/05/2025 at 14:00, 1 hour 43 minutes ago

Bonk, Inc. Highlights Major Ecosystem Milestone: Launch of Regulated BONK ETP on SIX Swiss Exchange

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 15:38, 4 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Unite Group plc, The
Published on 12/05/2025 at 15:36, 6 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Dowlais Group plc
Published on 12/05/2025 at 15:35, 7 minutes ago

Form 8.3 - The Vanguard Group, Inc.: American Axle & Manufacturing Holdings, Inc.
Published on 12/05/2025 at 15:33, 9 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Qualcomm Incorporated
Published on 12/05/2025 at 15:32, 10 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Alphawave IP Group plc

Les Echos

Published on 12/05/2025 at 15:10, 32 minutes ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 32 minutes ago

Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 1 hour 44 minutes ago

RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE
Published on 12/05/2025 at 08:45, 6 hours 58 minutes ago

Air Liquide va étendre et électrifier son unité de production d'oxygène à Shaanxi, soutenant ainsi l'engagement de la Chine à décarboner son industrie
Published on 12/05/2025 at 08:45, 6 hours 58 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry

View all LES ECHOS COMFI WIRE